Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-04-09
1999-03-23
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514354, 514355, A61K 3144
Patent
active
058860126
ABSTRACT:
Hypotensive mammals are treated to lower mean blood pressure by administering synergistic amounts of a calcium blocking agent together with a calcium supplement.
REFERENCES:
patent: 3975539 (1976-08-01), Koppe et al.
patent: 4402872 (1983-09-01), Bohn
patent: 4443549 (1984-04-01), Sadowski
patent: 4621093 (1986-11-01), Ulrich et al.
patent: 4703038 (1987-10-01), Garthoff et al.
patent: 4837171 (1989-06-01), Codington
patent: 4855300 (1989-08-01), Nandi et al.
patent: 4859665 (1989-08-01), Garthoff et al.
patent: 4906647 (1990-03-01), Kouchiwa et al.
patent: 5047235 (1991-09-01), Lossnitzer et al.
Federation Proceedings For Experimental Biology, vol. 45, No. 12, Nov. 12, 1986, Bethesda, MD; pp. 2739-2745, Lawrence M. Resnick et al., "Calcium Metabolism In Essential Hypertension: Relationship To Altered Renin System Activity."
Database WPI, Section Ch, Week 8809, Derwent Publications Ltd., London, GB; Class A96, AN 88-059842, XP002001479, & JP-A-63 014 715 (Zeria Shinyaku Kogy), Jan. 21, 1988.
Federation Proceedings For Experimental Biology, vol. 45, No. 12, Nov. 12, 1986, Bethesda, MD; pp. 2739-2745, Lawrence M. Resnick et al., "Calcium Metabolism In Essential Hypertension: Relationship To Altered Renin System Activity."
Bukoski et al., Biochem. and Biophys. Res. Comm., "Effect of 1.25 (OH).sub.2 Vitamin D.sub.3 and Ionized Ca.sup.2+ on .sup.45 Ca Uptake by Primary Cultures of Aortic Myocytes of Spontaneously Hypertensive and Wistar Kyoto Normotensive Rats", vol. 146, No. 3, pp. 1330-1335, 1987.
Park et al., American Physiological Society, "Calcium in the Control of Renin Release", pp. F22-F25, 1978.
Inoue et al., Biochem. and Biophys. Res. Comm., "1,25-Dihydroxyvitamin D.sub.3 Stimulated .sup.45 Ca.sup.2+ -Uptake by Cultured Vascular Smooth Muscle Cells Derived from Rat Aorta", vol. 152, No. 3, pp. 1388-1394, 1988.
Baran et al., The Journal of Clin. Inves., "1,25 Dihydroxyvitamin D Increases Hepatocyte Cytosolic Calcium Levels", vol. 77, No. 5, 1986.
Resnick et al., Federation Proc., "Calcium Metabolism in Essential Hypertension: Relationship to Altered Renin System Activity", vol. 45, No. 12, 1986.
Matsumura et al., The Journnal of Pharm., "Inhibitory Effects of Calcium Channel Agonists on Renin Release from Rat Kidney Cortical Slices", vol. 241, No. 3, 1987.
Kotchen et al., The American Journal of Cardiology, "Effects of Calcium on Renin and Aldosterone", vol. 62, pp. 41G-46G, 1988.
Park et al., American Journal of Physiology, "Calcium in the Control of Renin Secretion: Ca.sup.2+ Influx as an Inhibitory Siganl", vol. 240pp. F70-F74, Index Only. (1981).
Glick et al., Anal. Chem., "Development of a Solid-Substrate Room-Temperature Luminescence Immunoassay", vol. 60, No. 18, pp. 1982-1984, 1988.
Reichstein et al., Anal. Chem., "Laser-Excited Time-Resolved Solid-Phase Fluoroimmunoassays with the New Europium Chelate 4, 7-Bis-(chloro-sulfophenyl)-1,10-phenanthroline-2,9-dicarboxylic Acid as Label", vol. 60, No. 10, pp. 1069-1074, 1988.
Chem. Abstracts, vol. 109, p. 148, 1988.
Pharmacology, vol. 110, p. 43, 1989.
Fleckenstein et al., Zeitschrift fur Kreislaufforschung, "Zum Wirkungsmechanismus neuartiger Koronardilatatoren mit gleichzeitig Sauerstoff-einsparenden Myokare-Effekten, Prenylamin und Iproverstril", vol. 56, No. 7, pp. 716-745,. (1980).
Dixon et al., Enzymes, Third Edit., pp. 35-37, 1979.
Hermsmeyer et al., Annals New York Acad. of Sci., "Calcium Channel Modulation by Dihydropyridines in Vascular Smooth Muscle", pp. 24-31. (1980).
Fleckenstein, Annals New York Acad. of Sci., "The Calcium Channel of the Heart", pp. 1-15.
Benishin Christine G.
Lewanczuk Richard Z.
Pang Peter K. T.
Shan Jie
Criares Theodore J.
Pang Peter K. T.
LandOfFree
Method of treatment for disease associated with excessive PHF us does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment for disease associated with excessive PHF us, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment for disease associated with excessive PHF us will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2125712